-
Omeprazole A2845: Protocol and QC Guide
2026-09-18
This practical guide explains how to prepare, store, and quality-check Omeprazole (SKU A2845) for H+,K+-ATPase inhibition and gastric acid secretion research. It is intended for controlled laboratory experiments only, not for diagnosis, treatment, or other medical use.
-
HCAR3 Cryo-EM Structures Reveal Acifran Selectivity
2026-09-17
Ye et al. used cryo-EM and cellular cAMP assays to define how HCAR3 recognizes agonists and differs from HCAR2, with Acifran providing a shared ligand for direct structural comparison. The findings connect pocket geometry and aromatic residue identity to receptor selectivity, offering a mechanistic framework for lipid metabolism regulation and future HCAR3-directed compound design.
-
Bazedoxifene Workflow for ER Research
2026-09-17
Build more reproducible estrogen-receptor assays with Bazedoxifene, from concentration planning through bone-model validation. This guide connects tissue-selective pharmacology with endpoint-driven study design, practical controls, and troubleshooting for osteoporosis treatment research.
-
Ionophore Toxicity: Molecular Insights for Research
2026-09-17
Ekinci, Chłodowska, and Olejnik integrate clinical observations with molecular evidence to explain how polyether ionophores produce muscle and cardiac toxicity through ion dysregulation and impaired oxidative phosphorylation. The review provides a useful framework for designing mechanistic assays while emphasizing that dose, species, age, and drug interactions strongly influence interpretation.
-
Fulvestrant (ICI 182,780): An ERα Assay Playbook
2026-09-16
Fulvestrant (ICI 182,780) is more than an estrogen antagonist: it is a mechanistic perturbation tool for connecting ERα loss to MDM2 protein degradation, cell fate, and endocrine therapy resistance research. This assay-focused guide integrates breast cancer biology with a carefully bounded interpretation of estrogen–ER stress signaling.
-
HFM1, Zygotic Genome Activation, and Embryo Arrest
2026-09-15
A case-based study links a homozygous HFM1 variant to abnormal mRNA splicing, nuclear exclusion of the resulting protein, failed zygotic genome activation, and preimplantation embryo arrest. Its combination of patient-embryo profiling and mouse-embryo rescue provides a mechanistic framework for evaluating HFM1-related infertility while highlighting the need for larger validation studies.
-
Norepinephrine–Angiotensin II Conversion in Shock
2026-09-15
A post-hoc analysis of the ARAMIS trial estimated a 10:1 norepinephrine-to-angiotensin II conversion ratio, while showing limited variation by baseline renin and a lower ratio among patients recently exposed to angiotensin receptor blockers. The result offers a practical framework for dose translation, but its single-center, observational design limits direct generalization beyond the studied vasodilatory hypotension population.
-
Hexamethonium Bromide in Autonomic Research
2026-09-14
Use Hexamethonium Bromide to separate ganglionic transmission from downstream cardiovascular responses in conscious, telemetry-enabled models. This workflow translates sex-aware hypertension findings into practical controls for autonomic nervous system studies, neuronal signaling pathway research, and cholinergic neurotransmission inhibition.
-
Okadaic acid (A4540): Practical Protocol Guide
2026-09-14
Okadaic acid (A4540) is a serine/threonine phosphatase inhibitor for controlled PP2A- and PP1-dependent phosphorylation studies, apoptosis assays, and signal-transduction workflows. It is useful when phosphatase activity must be reduced experimentally, but it should not be treated as a universally selective reagent or used without matched solvent and concentration controls.
-
Flavopiridol Workflows for CDK and ER-Stress Studies
2026-09-13
Flavopiridol (L868275) offers a practical pan-CDK perturbation strategy for connecting cell-cycle arrest, apoptosis, transcriptional effects, and stress responses. This workflow emphasizes dose and time optimization, orthogonal readouts, and careful separation of validated cancer applications from exploratory intestinal stem-cell studies.
-
Concanamycin A and the Lysosomal Stress Checkpoint
2026-09-12
A translational framework for using Concanamycin A to interrogate V-ATPase-dependent lysosomal stress, AMPK–p62–NRF2 signaling, apoptosis, and invasion while separating mechanistic effects from nonspecific toxicity.
-
EZ Cap™ Cre mRNA (m1Ψ) for Cre Editing
2026-09-12
EZ Cap™ Cre mRNA (m1Ψ) is a Cap 1, polyadenylated Cre recombinase mRNA designed for transient loxP recombination studies. Its m1Ψ modification, RNase-controlled handling, and defined cold-storage formulation support reproducible gene editing mRNA and functional protein mRNA workflows.
-
SCH772984 HCl: ERK1/2 Inhibitor Workflow
2026-09-11
SCH772984 HCl enables controlled interrogation of ERK1/2 signaling in BRAF- and RAS-driven cancer models, while also supporting hypothesis-driven studies of MAPK activity in stem-cell and telomerase assays. This guide links target engagement, antiproliferative readouts, resistance biology, and the APEX2–TERT findings into a practical experimental workflow.
-
L-Alanyl-L-glutamine for GI Barrier Assays
2026-09-11
Build reproducible intestinal barrier, oxidative-stress, and inflammation workflows with a water-soluble dipeptide designed for controlled nutritional support. This guide pairs practical dosing and QC guidance with a careful interpretation of antiviral screening evidence, helping researchers separate barrier-protection experiments from infection-inhibition claims.
-
Dextromethorphan Hydrobromide: Evidence-to-Assay Framework
2026-09-10
Dextromethorphan hydrobromide is examined as a functional NMDA receptor antagonist through an evidence-to-assay framework. This guide connects ion-channel pharmacology, neuroprotection research, and lessons from translational assay design without overstating preclinical evidence.